Obviousness

The provided patent document, US12138052B1, does not contain a discrete "Prior Art section" that lists specific patent or publication references for an obviousness analysis under 35 U.S.C. § 103. Therefore, this analysis will rely on the descriptions of conventional systems, known problems, and techniques that are presented as prior art within the patent's "BACKGROUND" section.

A Person Having Ordinary Skill in the Art (PHOSITA) in the field of medical blood sampling devices would be familiar with the challenges and existing practices described in the patent's background.

Elements of the Invention (as summarized in the patent):

A representative claim of the invention, as described in the "SUMMARY" section, includes:

1. A blood sequestration device.
2. An inlet port and an outlet port.
3. A sequestration chamber connected with the inlet port, the sequestration chamber having a vent comprising an an air permeable blood barrier.
4. A sampling channel having a proximal end connected with the inlet port and a distal end connected with the outlet port.

The core concept is to provide a device that passively and automatically sequesters an initial, potentially contaminated aliquot of blood, allowing subsequent uncontaminated blood to be collected through a separate channel.

Prior Art Concepts and Motivation for Combination:

The patent's "BACKGROUND" section explicitly describes several pieces of prior art and the problems associated with them, which would provide clear motivation for a PHOSITA to combine known elements to arrive at the claimed invention:

1. Known Problem of Blood Culture Contamination: The patent highlights that "Blood culture contamination can lead to a false positive culture result and/or significant increase in healthcare related costs." It further explains that contamination can occur from "improper skin antisepsis, improper collection tube disinfection, and contamination of the initial blood draw which may then skew results." Specifically, it notes that "False positive blood cultures are typically a result of poor sampling techniques... Contamination may occur from improper or incomplete disinfection of the skin area in and around the puncture site. It may also occur from the coring of the skin by the needle during insertion, with the cored skin cells and any associated contamination being pulled into the sample." This establishes the need for uncontaminated blood samples.

2. Known Solution (and its Drawbacks): Discarding the Initial Aliquot: The patent states that "Some conventional systems and techniques for reducing blood culture contamination include discarding the initial aliquot of blood taken from central venous catheters, venipunctures, and other vascular access systems." This demonstrates that the general concept of isolating the initial, potentially contaminated blood is already known and practiced.

3. Motivation to Improve the Known Solution: Crucially, the patent explicitly details the deficiencies of the existing discarding methods: "However, these systems require the user to mechanically manipulate an intravascular device, or require a complex series of steps that are difficult to ensure being followed." This statement clearly identifies a strong motivation for a PHOSITA to develop a system that automates or simplifies the process of discarding the initial aliquot, thereby reducing user variability and ensuring proper procedure.

4. Known Fluidic Components and Principles: A PHOSITA would be aware of standard medical fluid handling components:

   • Patient needles, sample needles, and tubing/pathways: These are fundamental to any blood sampling system, as described in the patent's context (e.g., "blood culture collection kits generally consist of a 'butterfly' set, infusion set, or other type of venipuncture device... and aerobic and anaerobic blood culture bottles. Various different bottles are also available depending on the test requirements.").
   • Vacutainer-type collection devices: The patent refers to these as a standard "blood collection tube formed of a sterile glass or plastic tube with a closure that is evacuated to create a vacuum inside the tube to facilitate the draw of a predetermined volume of liquid such as blood." The invention contemplates use with such devices.
   • Vents and air-permeable liquid-impermeable barriers: In any passive fluid filling system where a liquid displaces air, a vent is a fundamental requirement. The use of materials that are "air permeable but substantially blood impermeable" (e.g., hydrophobic membranes, filters) to allow air to escape but prevent liquid leakage is a well-known engineering principle in medical and fluidic device design. The patent's detailed description of "air permeable blood barrier" explicitly includes "hydrophobic membranes and coatings, a hydrophilic membrane or coating combined with a hydrophobic membrane or coating, mesh, a filter, a mechanical valve, antimicrobial material, or any other means of allowing air to be displaced from the sequestration chamber 55 as it is filled with blood."

Obvious Combination:

A PHOSITA, faced with the problems of manual blood discard techniques, would be motivated to automate this known process. The combination would proceed as follows:

• Automating the "discard": Instead of manually manipulating a device to discard blood, a PHOSITA would conceive of a dedicated "sequestration chamber" placed in the blood flow path after the patient needle. This chamber would receive the initial "discard" volume.
• Passive filling of the sequestration chamber: To enable the patient's own blood pressure to passively fill this chamber (addressing the issue of "forceful aspiration" causing lysis and vein collapse, as also mentioned in the background), the chamber would require a "vent" to allow displaced air to escape.
• Containment and Cleanliness: To ensure the sequestered blood is contained and does not contaminate the environment or allow external air/contaminants back in, the vent would obviously incorporate an "air permeable blood barrier" (e.g., a hydrophobic filter). This known technology allows air out but stops blood from leaking, and is a standard solution for such venting needs in medical devices.
• Subsequent Collection Pathway: After the initial aliquot is sequestered, the remaining, uncontaminated blood needs to be directed to the collection device. This necessitates a "sampling channel" that bypasses the now-filled sequestration chamber and leads to the outlet port. The fluidic arrangement would naturally be designed such that blood preferentially enters the empty, vented sequestration chamber first, and then flows to the (initially sealed) sampling channel once the sequestration chamber is full (as implicitly described by the invention's operation where patient's blood pressure fills the sequestration chamber before vacuum from a Vacutainer draws blood through the sampling channel).

The patent itself supports this obviousness by stating that its systems "eliminate user variability in disinfection, and also eliminate the risk of skin cells getting into the blood culture sample," and that "the withdrawal of blood is accomplished passively by use of the patient's own blood pressure, thereby reducing the risk of vein collapse and eliminating any additional user steps over current practice." These are direct improvements over the acknowledged deficiencies of the prior art, achievable by combining known concepts in an obvious manner.

Therefore, the combination of the known practice of discarding initial blood aliquots, the recognized problems with manual discard, and the use of standard fluidic and filtration components to create an automated, passive sequestration device with a separate sampling channel would have been obvious to a PHOSITA seeking to improve blood sampling techniques.